Clinical trials on ATC

  • CT-EU-00117038

    NCT05668585

    This is a Phase 1/2 clinical trial looking at a new investigational drug called CFT1946 for treating certain types of solid tumors that have a specific genetic mutation called BRAF V600. This includes cancers like melanoma, non-small cell lung cancer, colorectal cancer, and a type of thyroid cancer called anaplastic thyroid cancer.

    In the first part of the study, called Phase 1, the main goals are to determine the highest safe dose of CFT1946 that can be given and to look at side effects. CFT1946 will be given by itself (monotherapy) or combined with two other approved drugs, trametinib or cetuximab.

    If safe doses are found in Phase 1, the study will then move to Phase 2. In this part, the main goals are to see if the treatments shrink tumors, measured by overall response rate and disease control rate, and how long any responses last, called duration of response.

    The study involves taking CFT1946 and possibly the other drugs by mouth or intravenously on a set schedule, along with regular monitoring, scans, and blood tests. Participation could last up to around 43 months.

    • CFT1946
    • Trametinib
    • Cetuximab